Latest Safety News

Tetratherix has successfully completed the second safety review of its TetraDerm clinical trial's second cohort, showing no adverse events and confirming a strong safety profile. The trial now progresses to its final phase, targeting a growing reconstructive surgery market.

DPM Metals has once again met its gold production guidance for 2025, marking eleven consecutive years of hitting targets, while preparing for a significant ramp-up at its Vareš operation.

Entropy Neurodynamics reports compelling Phase 2a results showing oral psilocybin dramatically reduces binge eating episodes and related psychiatric symptoms, supporting advancement of its lead IV psilocin candidate.

Firebird Metals has commissioned its proprietary equipment for producing advanced lithium-manganese-rich cathode materials at its China pilot plant, aiming to start production in February 2026 with customer samples planned for later in the year. The project is co-funded by strategic partner Taza Metal Technologies, reducing capital risk and accelerating development.

ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.

Clinuvel Pharmaceuticals has initiated dosing in a preclinical study of its novel controlled-release injectable peptide platform, VLRX-L, aiming to enhance drug delivery for melanocortin-based therapies. Preliminary results are expected in the second half of 2026.

Cyclopharm secures a landmark deal with Lucile Packard Children’s Hospital Stanford to introduce Technegas, marking the first dedicated children’s hospital in the US to adopt this advanced lung imaging technology.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its Vision-MR Diagnostic Catheter, paving the way for commercial sales in the US electrophysiology market.

Capstone Copper Corp. has been hit by a strike at its Mantoverde mine in Chile, with Union #2 representing 22% of the workforce initiating industrial action that could reduce production by up to 30%. The company is committed to resolving the dispute through dialogue while maintaining safe operations.

Codan Limited has reported a strong first-half FY26 trading update, with revenue up 29% and underlying net profit after tax soaring 52%, driven by robust metal detection and communications segments.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.

Elsight Limited has secured a US$460,000 purchase order from a U.S. public safety customer, marking a significant commercial milestone amid accelerating FAA regulations for drone operations beyond visual line of sight.